Protein C inhibitor regulates both cathepsin L activity and cell-mediated tumor cell migration

Biochimica et Biophysica Acta - General Subjects

Volumn 1800, Issue 6, 2010, Pages 580-590

  Fortenberry, Yolanda M ^a   Brandal, Stephanie ^a   Bialas, Ryan C ^b   Church, Frank C ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer cells; Cathepsins; Cell migration; Heparin; Protein C inhibitor; Serpins; SiRNA

Indexed keywords

ARGININE; CATHEPSIN L; PHENYLALANINE; PLASMINOGEN ACTIVATOR INHIBITOR 3; SMALL INTERFERING RNA; THREONINE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL LYSATE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG SPECIFICITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; PRIORITY JOURNAL; WILD TYPE;

BASE SEQUENCE; BREAST NEOPLASMS; CATHEPSIN L; CELL LINE, TUMOR; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MUTAGENESIS, SITE-DIRECTED; NEOPLASM METASTASIS; PROTEIN C INHIBITOR;

EID: 77952239319     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2010.03.003     Document Type: Article

References (59)

1. Silverman G.A., Bird P.I., Carrell R.W., Church F.C., Coughlin P.B., Gettins P.G.W., Irving J.A., Lomas D.A., Luke C.J., Moyer R.W., Pemberton P.A., Remold-O'Donnell E., Salvesen G.S., Travis J., Whisstock J.C. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 2001, 276:33293-33296.
2. Hwang S.R., Stoka V., Turk V., Hook V.Y. The novel bovine serpin endopin 2C demonstrates selective inhibition of the cysteine protease cathepsin L compared to the serine protease elastase, in cross-class inhibition. Biochemistry 2005, 44:7757-7767.
3. Bjork I., Nordling K., Raub-Segall E., Hellman U., Olson S.T. Inactivation of papin by antithrombin due to autolytic digestion: a model of serpin inactivation of cysteine proteinases. Biochem. J. 1998, 335.
4. Welss T., Sun J., Irving J.A., Blum R., Smith A.I., Whisstock J.C., Pike R.N., von Mikecz A., Ruzicka T., Bird P.I., Abts H.F. Hurpin is a selective inhibitor of lysosomal cathepsin L and protects keratinocytes from ultraviolet-induced apoptosis. Biochemistry 2003, 42:7381-7389.
5. Masumoto K., Sakata Y., Arima K., Nakao I., Izuhara K. Inhibitory mechanism of a cross-class serpin, the squamous cell carcinoma antigen 1. J. Biol. Chem. 2003, 278:45296-45304.
6. Irving J.A., Shushanov S.S., Pike R.N., Popova E.Y., Bromme D., Coetzer T.H., Bottomley S.P., Boulynko I.A., Grigoryev S.A., Whisstock J.C. Inhibitory activity of a heterochromatin-associated serpin (MENT) against papain-like cysteine proteinases affects chromatin structure and blocks cell proliferation. J. Biol. Chem. 2002, 277:13192-13201.
7. Dubin G. Proteinaceous cysteine protease inhibitors. Cell Mol. Life Sci. 2005, 62:653-669.
8. Oksjoki S., Soderstrom M., Vuorio E., Anttila L. Differential expression patterns of cathepsins B, H, K, L and S in the mouse ovary. Mol. Hum. Reprod. 2001, 7:27-34.
9. Tsuge H., Nishimura T., Tada Y., Asao T., Turk D., Turk V., Katunuma N. Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex. Biochem. Biophys. Res. Commun. 1999, 266:411-416.
10. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
11. Nomura T., Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J. Med. Invest. 2005, 52:1-9.
12. Lah T.T., Duran Alonso M.B., Van Noorden C.J. Antiprotease therapy in cancer: hot or not?. Exp. Opin. Biol. Ther. 2006, 6:257-279.
13. Herszenyi L., Plebani M., Carraro P., De Paoli M., Roveroni G., Cardin R., Tulassay Z., Naccarato R., Farinati F. The role of cysteine and serine proteases in colorectal carcinoma. Cancer 1999, 86:1135-1142.
14. Thomssen C., Oppelt P., Janicke F., Ulm K., Harbeck N., Hofler H., Kuhn W., Graeff H., Schmitt M. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Res. 1998, 18:2173-2180.
15. Gocheva V., Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007, 6:60-64.
16. Skrzydlewska E., Sulkowska M., Wincewicz A., Koda M., Sulkowski S. Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer. World J. Gastroenterol. 2005, 11:4225-4229.
17. Nathaniel R., MacNeill A.L., Wang Y.X., Turner P.C., Moyer R.W. Cowpox virus CrmA, Myxoma virus SERP2 and baculovirus P35 are not functionally interchangeable caspase inhibitors in poxvirus infections. J. Gen. Virol. 2004, 85:1267-1278.
18. Petit F., Bertagnoli S., Gelfi J., Fassy F., Boucraut-Baralon C., Milon A. Characterization of a myxoma virus-encoded serpin-like protein with activity against interleukin-1 beta-converting enzyme. J. Virol. 1996, 70:5860-5866.
19. Turner P.C., Sancho M.C., Thoennes S.R., Caputo A., Bleackley R.C., Moyer R.W. Myxoma virus Serp2 is a weak inhibitor of granzyme B and interleukin-1beta-converting enzyme in vitro and unlike CrmA cannot block apoptosis in cowpox virus-infected cells. J. Virol. 1999, 73:6394-6404.
20. Schick C., Pemberton P.A., Shi G.P., Kamachi Y., Cataltepe S., Bartuski A.J., Gornstein E.R., Bromme D., Chapman H.A., Silverman G.A. Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. Biochemistry 1998, 37:5258-5266.
21. Al-Khunaizi M., Luke C.J., Askew Y.S., Pak S.C., Askew D.J., Cataltepe S., Miller D., Mills D.R., Tsu C., Bromme D., Irving J.A., Whisstock J.C., Silverman G.A. The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases. Biochemistry 2002, 41:3189-3199.
22. Jayakumar A., Kang Y., Frederick M.J., Pak S.C., Henderson Y., Holton P.R., Mitsudo K., Silverman G.A., AK E.L.-N., Bromme D., Clayman G.L. Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis. Arch. Biochem. Biophys. 2003, 409:367-374.
23. Pike R.N., Buckle A.M., le Bonniec B.F., Church F.C. Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans. Febs J. 2005, 272:4842-4851.
24. Geiger M., Krebs M., Jerabek I., Binder B.R. Protein C inhibitor (PCI) and heparin cofactor II (HCII): Possible alternative roles of these heparin-binding serpins outside the hemostatic system. Immunopharm. 1997, 36:279-284.
25. Geiger M. Protein C inhibitor, a serpin with functions in- and outside vascular biology. Thromb. Haemost. 2007, 97:343-347.
26. Fortenberry Y.M., Whinna H.C., Cooper S.T., Myles T., Leung L.L., Church F.C. Essential thrombin residues for inhibition by protein C inhibitor with the cofactors heparin and thrombomodulin. J. Thromb. Haemost. 2007, 5:1486-1492.
27. Rau J.C., Beaulieu L.M., Huntington J.A., Church F.C. Serpins in thrombosis, hemostasis and fibrinolysis. J. Thromb. Haemost. 2007, 5(Suppl 1):102-115.
28. Li W., Adams T.E., Kjellberg M., Stenflo J., Huntington J.A. Structure of native protein C inhibitor provides insight into its multiple functions. J. Biol. Chem. 2007, 282:13759-13768.
29. Pemberton P.A., Stein P.E., Pepys M.B., Potter J.M., Carrell R.W. Hormone binding globulins undergo serpin conformational change in inflammation. Nature 1988, 336:257-258.
30. Suda S.A., Gettins P.G., Patston P.A. Linkage between the hormone binding site and the reactive center loop of thyroxine binding globulin. Arch. Biochem. Biophys. 2000, 384:31-36.
31. Pratt C.W., Church F.C. Heparin binding to protein C inhibitor. J. Biol. Chem. 1992, 267:8789-8794.
32. Rehault S.M., Zechmeister-Machhart M., Fortenberry Y.M., Malleier J., Binz N.M., Cooper S.T., Geiger M., Church F.C. Characterization of recombinant human protein C inhibitor expressed in Escherichia coli. Biochim. Biophys. Acta 2005, 1748:57-65.
33. Phillips J.E., Cooper S.T., Potter E.E., Church F.C. Mutagenesis of recombinant protein C inhibitor reactive site residues alters target proteinase specificity. J. Biol. Chem. 1994, 269:16696-16700.
34. Fortenberry Y.M., Whinna H.C., Gentry H.R., Myles T., Leung L.L., Church F.C. Molecular mapping of the thrombin-heparin cofactor II complex. J. Biol. Chem. 2004, 279:43237-43244.
35. Fortenberry Y., Liu J., Lindberg I. The role of the 7B2 CT peptide in the inhibition of prohormone convertase 2 in endocrine cell lines. J. Neurochem. 1999, 73:994-1003.
36. Whitley B.R., Church F.C. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1. Int. J. Oncol. 2005, 27:749-757.
37. Zajc I., Sever N., Bervar A., Lah T.T. Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. Cancer Lett. 2002, 187:185-190.
38. Asanuma K., Yoshikawa T., Hayashi T., Akita N., Nakagawa N., Hamada Y., Nishioka J., Kamada H., Gabazza E.C., Ido M., Uchida A., Suzuki K. Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity. Int. J. Cancer 2007, 121:955-965.
39. Whitley B.R., Palmieri D., Twerdi C., Church F.C. Expression of active plasminogen activator inhibitor-1 regulates cell migration and invasion in breast and gynecological cancer cells. Exp. Cell Res. 2004, 296:151-162.
40. Holst-Hansen C., Johannessen B., Hoyer-Hansen G., Romer J., Ellis V., Brunner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin. Exp. Metastasis 1996, 14:297-307.
41. Caserman S., Kenig S., Sloane B.F., Lah T.T. Cathepsin L splice variants in human breast cell lines. Biol. Chem. 2006, 387:629-634.
42. Gal S., Gottesman M.M. Isolation and sequence of a cDNA for human pro-(cathepsin L). Biochem. J. 1988, 253:303-306.
43. Higgins W.J., Fox D.M., Kowalski P.S., Nielsen J.E., Worrall D.M. Heparin enhances serpin inhibition of the cysteine protease, cathepsin L. J. Biol. Chem. 2010, 285:3722-3729.
44. Hook V.Y., Purviance R.T., Azaryan A.V., Hubbard G., Krieger T.J. Purification and characterization of alpha 1-antichymotrypsin-like protease inhibitor that regulates prohormone thiol protease involved in enkephalin precursor processing. J. Biol. Chem. 1993, 268:20570-20577.
45. Ecke S., Geiger M., Resch I., Jerabek I., Stingl L., Maier M., Binder B.R. Inhibition of tissue kallikrein by protein C inhibitor. Evidence for identity of protein C inhibitor with the kallikrein binding protein. J. Biol. Chem. 1992, 267:7048-7052.
46. Ecke S., Geiger M., Binder B.R. Heparin binding of protein-C inhibitor-analysis of the effect of heparin on the interaction of protein-C inhibitor with tissue kallikrein. Eur. J. Biochem. 1997, 248:475-480.
47. Bode W., Huber R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 1992, 204:433-451.
48. Luke C., Schick C., Tsu C., Whisstock J.C., Irving J.A., Bromme D., Juliano L., Shi G.P., Chapman H.A., Silverman G.A. Simple modifications of the serpin reactive site loop convert SCCA2 into a cysteine proteinase inhibitor: a critical role for the P3' proline in facilitating RSL cleavage. Biochemistry 2000, 39:7081-7091.
49. Suzuki K., Kise H., Nishioka J., Hayashi T. The interaction among protein C inhibitor, prostate-specific antigen, and the semenogelin system. Semin. Thromb. Hemost. 2007, 33:46-52.
50. Castello R., Landete J.M., Espana F., Vazquez C., Fuster C., Almenar S.M., Ramon L.A., Radtke K.P., Estelles A. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thromb. Res. 2007, 120:753-762.
51. Palmieri D., Lee J.-W., Juliano R.L., Church F.C. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J. Biol. Chem. 2002, 277:40950-40957.
52. Lah T.T., Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 1998, 379:125-130.
53. Levicar N., Dewey R.A., Daley E., Bates T.E., Davies D., Kos J., Pilkington G.J., Lah T.T. Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther. 2003, 10:141-151.
54. Krueger S., Kellner U., Buehling F., Roessner A. Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype. Cancer Gene Ther. 2001, 8:522-528.
55. Colella R., Casey S.F. Decreased activity of cathepsins L+B and decreased invasive ability of PC3 prostate cancer cells. Biotech. Histochem. 2003, 78:101-108.
56. Dohchin A., Suzuki J.I., Seki H., Masutani M., Shiroto H., Kawakami Y. Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma. Cancer 2000, 89:482-487.
57. Montcourrier P., Silver I., Farnoud R., Bird I., Rochefort H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin. Exp. Metastasis 1997, 15:382-392.
58. Kirschke H., Eerola R., Hopsu-Havu V.K., Bromme D., Vuorio E. Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur. J. Cancer 2000, 36:787-795.
59. Rousselet N., Mills L., Jean D., Tellez C., Bar-Eli M., Frade R. Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. 2004, 64:146-151.